Immune checkpoint inhibitors that block the immunosuppressive receptors such as cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and PD-1 can reverse the dampened antitumor immune response of T cells in the tumor microenvironment and trigger anticancer properties of infiltrating T cells [62]. The gene discussed is CTLA4; the disease is neoplasm.